News of Note—Abzena invests in California, Catalent in China

Cancer in newspaper clipping
(Pixabay)

> Abzena is investing $20 million to add two manufacturing suites at the 500 liter and 2000 liter scale, at its manufacturing facility in San Diego, California. Release

> Catalent Pharma Solutions will invest $2.5 million in a second clinical supply facility in Shanghai, China, which will employ about 100 people when it opens in early 2019. Release

> The FDA is instituting new protocols to gather data from sterile injectable manufacturers in an effort to raise quality and avoid shortages. Release

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

> Dave Tudor, Ph.D., previously head of manufacturing strategy for GlaxoSmithKline, has been appointed managing director of the Medicines Manufacturing Innovation Centre, a collaboration among GSK, AstraZeneca, CPI and the University of Strathclyde in Scotland. Release

> For the first time in 30 years the U.S. will have a domestic supply of Iodine-131 (I-131), a critical radioisotope for diagnosing and treating thyroid cancer and hyperthyroidism. The supply is being produced by the University of Missouri. Release

Suggested Articles

Lonza is on deck to help manufacture AstraZeneca's COVID-fighting antibody duo at its Portsmouth, New Hampshire site.

Japanese regulators approved the manufacturing of Novartis' Kymriah at a Kobe site, adding the first Asian facility to the therapy's network.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.